Beam Therapeutics Inc (NASDAQ: BEAM) kicked off On Friday, down -4.46% from the previous trading day, before settling in for the closing price of $19.71. Over the past 52 weeks, BEAM has traded in a range of $13.52-$35.25.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -20.88% over the past five years. While this was happening, its average annual earnings per share was recorded -0.41%. With a float of $89.78 million, this company’s outstanding shares have now reached $100.56 million.
Let’s look at the performance matrix of the company that is accounted for 483 employees. In terms of profitability, gross margin is 74.06%, operating margin of -677.47%, and the pretax margin is -609.18%.
Beam Therapeutics Inc (BEAM) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Beam Therapeutics Inc is 10.71%, while institutional ownership is 93.39%. The most recent insider transaction that took place on Jul 30 ’25, was worth 991,667. In this transaction See Remark 1 of this company sold 48,374 shares at a rate of $20.50, taking the stock ownership to the 2,073,665 shares. Before that another transaction happened on Jul 03 ’25, when Company’s Chief Medical Officer sold 876 for $20.12, making the entire transaction worth $17,625. This insider now owns 64,864 shares in total.
Beam Therapeutics Inc (BEAM) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.09 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -0.41% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -0.84% during the next five years compared to -20.88% drop over the previous five years of trading.
Beam Therapeutics Inc (NASDAQ: BEAM) Trading Performance Indicators
Take a look at Beam Therapeutics Inc’s (BEAM) current performance indicators. Last quarter, stock had a quick ratio of 8.81. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 29.78.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.61, a number that is poised to hit -1.11 in the next quarter and is forecasted to reach -4.64 in one year’s time.
Technical Analysis of Beam Therapeutics Inc (BEAM)
Beam Therapeutics Inc (NASDAQ: BEAM) saw its 5-day average volume 2.31 million, a positive change from its year-to-date volume of 2.05 million. As of the previous 9 days, the stock’s Stochastic %D was 6.82%.
During the past 100 days, Beam Therapeutics Inc’s (BEAM) raw stochastic average was set at 35.45%, which indicates a significant increase from 4.57% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.27 in the past 14 days, which was lower than the 1.32 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $18.62, while its 200-day Moving Average is $22.72. Nevertheless, the first resistance level for the watch stands at $19.33 in the near term. At $19.84, the stock is likely to face the second major resistance level. The third major resistance level sits at $20.18. If the price goes on to break the first support level at $18.48, it is likely to go to the next support level at $18.14. The third support level lies at $17.63 if the price breaches the second support level.
Beam Therapeutics Inc (NASDAQ: BEAM) Key Stats
The company with the Market Capitalisation of 1.89 billion has total of 100,557K Shares Outstanding. Its annual sales at the moment are 63,520 K in contrast with the sum of -376,740 K annual income. Company’s last quarter sales were recorded 7,470 K and last quarter income was -109,270 K.
